# ANOS1

## Overview
The ANOS1 gene encodes the protein anosmin-1, a secreted glycoprotein that plays a pivotal role in neural development and angiogenesis. Anosmin-1 is characterized by its complex structure, which includes a WAP domain and multiple fibronectin type III domains, facilitating its interaction with various receptors and proteins (Matsushima2020Anosmin1). Functionally, anosmin-1 is involved in the modulation of fibroblast growth factor receptor 1 (FGFR1) signaling, crucial for neurite outgrowth and neuronal differentiation, as well as in promoting angiogenic activities through its interaction with vascular endothelial growth factor receptor 2 (VEGFR2) (Matsushima2020Anosmin1; GonzálezMartínez2004Anosmin1). Mutations in the ANOS1 gene are linked to Kallmann syndrome, a condition characterized by anosmia and hypogonadotropic hypogonadism, underscoring the gene's clinical significance (Maione2018GENETICS; Gach2020Expanding).

## Structure
Anosmin-1, encoded by the ANOS1 gene, is a secreted glycoprotein involved in neural development and angiogenesis. The protein features several distinct domains, including a WAP domain and four fibronectin type III domains, which are crucial for its interactions with other proteins and receptors (Matsushima2020Anosmin1). The N-terminal region of anosmin-1 includes a cysteine-box domain, which, along with the WAP domain and fibronectin-like type III repeats, is essential for its interaction with VEGFR2, a receptor involved in angiogenesis (Matsushima2020Anosmin1).

Anosmin-1 undergoes glycosylation, a common post-translational modification that may influence its stability and function (Matsushima2020Anosmin1). The protein's interaction with VEGFR2 and its role in activating downstream signaling pathways, such as the PLCγ1-PKC pathway, are critical for endothelial cell migration, proliferation, and tube formation (Matsushima2020Anosmin1). While the specific details of its primary, secondary, tertiary, and quaternary structures are not provided, the functional domains and post-translational modifications highlight its complex role in cellular processes. There is no mention of splice variant isoforms in the available context.

## Function
The ANOS1 gene encodes the anosmin-1 protein, which plays a crucial role in the development of the olfactory system and the migration of gonadotropin-releasing hormone (GnRH) neurons. Anosmin-1 is involved in modulating fibroblast growth factor receptor 1 (FGFR1) signaling, which is essential for neurite outgrowth and neuronal differentiation. It acts as a co-ligand that enhances FGFR1 signaling, leading to cytoskeletal reorganization and neurite outgrowth through pathways involving MAPK phosphorylation and Cdc42/Rac1 activation (Esteban2012The; GonzálezMartínez2004Anosmin1).

Anosmin-1 also plays a significant role in angiogenesis, particularly in the olfactory bulb, by interacting with vascular endothelial growth factor receptor 2 (VEGFR2). This interaction promotes endothelial cell migration, proliferation, and tube formation, enhancing angiogenic activities (Matsushima2020Anosmin1).

Additionally, anosmin-1 is involved in cell adhesion and migration, particularly affecting oligodendrocyte precursors and their interaction with the extracellular matrix. It enhances cell adhesion and migration, which are critical for proper neural development (Bribián2008A). Mutations in the ANOS1 gene can disrupt these processes, leading to conditions such as Kallmann syndrome.

## Clinical Significance
Mutations in the ANOS1 gene are primarily associated with Kallmann syndrome (KS), a form of congenital hypogonadotropic hypogonadism (CHH) characterized by a lack of spontaneous pubertal development and anosmia, or loss of the sense of smell (Maione2018GENETICS; Gach2020Expanding). ANOS1 mutations are linked to the X-linked recessive form of KS, affecting the development and migration of olfactory and gonadotropin-releasing hormone (GnRH) neurons (Gonçalves2017Expanding; Chu2023Mutation). 

The gene is located on the X chromosome, and its mutations often result in frameshifts, nonsense mutations, or deletions, leading to truncated or absent anosmin-1 protein, which is crucial for normal neuronal development (de2016ANOS1:; Neocleous2020GnRH). These genetic alterations can cause additional symptoms such as renal agenesis, bimanual synkinesis, and skeletal anomalies (Zhang2020Identification; Kałużna2021Defects). 

The penetrance of KS in patients with ANOS1 mutations is nearly complete, with most exhibiting both CHH and anosmia (Maione2018GENETICS). The genetic complexity and heterogeneity of ANOS1 mutations underscore the importance of genetic screening for accurate diagnosis and understanding of KS (Gonçalves2017Expanding; Kim2018Targeted).

## Interactions
Anosmin-1, encoded by the ANOS1 gene, is involved in various protein interactions that are crucial for its biological functions. It interacts with fibroblast growth factor receptor 1 (FGFR1) and heparan sulfate proteoglycans (HSPG), forming complexes that are essential for cell adhesion, migration, and neurite outgrowth. The interaction with FGFR1 involves the first fibronectin-like type III repeat and the WAP domain of anosmin-1, which enhances FGFR1 signaling (de2016ANOS1:; Matsushima2020Anosmin1).

Anosmin-1 also binds to vascular endothelial growth factor receptor 2 (VEGFR2), acting as a ligand similar to VEGF-A. This interaction activates downstream signaling pathways, including phospholipase Cγ1 (PLCγ1) and protein kinase C (PKC), promoting endothelial cell migration, proliferation, and tube formation, which are critical for angiogenesis in the olfactory bulb (Matsushima2020Anosmin1).

Additionally, anosmin-1 interacts with other extracellular matrix components such as laminin, fibronectin, and integrin-beta, influencing cell adhesion and migration. These interactions are independent of FGF2-FGFR1 signaling, highlighting the multifaceted role of anosmin-1 in cellular processes (de2016ANOS1:).


## References


[1. (Gach2020Expanding) Agnieszka Gach, Iwona Pinkier, Maria Szarras-Czapnik, Agata Sakowicz, and Lucjusz Jakubowski. Expanding the mutational spectrum of monogenic hypogonadotropic hypogonadism: novel mutations in anos1 and fgfr1 genes. Reproductive Biology and Endocrinology, January 2020. URL: http://dx.doi.org/10.1186/s12958-020-0568-6, doi:10.1186/s12958-020-0568-6. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12958-020-0568-6)

[2. (Neocleous2020GnRH) Vassos Neocleous, Pavlos Fanis, Meropi Toumba, George A. Tanteles, Melpo Schiza, Feride Cinarli, Nicolas C. Nicolaides, Anastasis Oulas, George M. Spyrou, Christos S. Mantzoros, Dimitrios Vlachakis, Nicos Skordis, and Leonidas A. Phylactou. Gnrh deficient patients with congenital hypogonadotropic hypogonadism: novel genetic findings in anos1, rnf216, wdr11, fgfr1, chd7, and polr3a genes in a case series and review of the literature. Frontiers in Endocrinology, August 2020. URL: http://dx.doi.org/10.3389/fendo.2020.00626, doi:10.3389/fendo.2020.00626. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2020.00626)

[3. (Zhang2020Identification) Qin Zhang, Hong‐hui He, Muhammad Usman Janjua, Fang Wang, You‐bo Yang, Zhao‐hui Mo, Jun Liu, and Ping Jin. Identification of two novel mutations in three chinese families with kallmann syndrome using whole exome sequencing. Andrologia, May 2020. URL: http://dx.doi.org/10.1111/and.13594, doi:10.1111/and.13594. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/and.13594)

[4. (Maione2018GENETICS) Luigi Maione, Andrew A Dwyer, Bruno Francou, Anne Guiochon-Mantel, Nadine Binart, Jérôme Bouligand, and Jacques Young. Genetics in endocrinology: genetic counseling for congenital hypogonadotropic hypogonadism and kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. European Journal of Endocrinology, 178(3):R55–R80, March 2018. URL: http://dx.doi.org/10.1530/eje-17-0749, doi:10.1530/eje-17-0749. This article has 112 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1530/eje-17-0749)

[5. (Bribián2008A) Ana Bribián, Pedro F. Esteban, Diego Clemente, Nadia Soussi‐Yanicostas, Jean‐Léon Thomas, Bernard Zalc, and Fernando de Castro. A novel role for anosmin‐1 in the adhesion and migration of oligodendrocyte precursors. Developmental Neurobiology, 68(13):1503–1516, September 2008. URL: http://dx.doi.org/10.1002/dneu.20678, doi:10.1002/dneu.20678. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/dneu.20678)

[6. (Gonçalves2017Expanding) C.I. Gonçalves, F. Fonseca, T. Borges, F. Cunha, and M.C. Lemos. Expanding the genetic spectrum ofanos1mutations in patients with congenital hypogonadotropic hypogonadism. Human Reproduction, January 2017. URL: http://dx.doi.org/10.1093/humrep/dew354, doi:10.1093/humrep/dew354. This article has 8 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/humrep/dew354)

[7. (Kim2018Targeted) Ja Hye Kim, Go Hun Seo, Gu-Hwan Kim, Juyoung Huh, Il Tae Hwang, Ja-Hyun Jang, Han-Wook Yoo, and Jin-Ho Choi. Targeted gene panel sequencing for molecular diagnosis of kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Experimental and Clinical Endocrinology &amp; Diabetes, 127(08):538–544, September 2018. URL: http://dx.doi.org/10.1055/a-0681-6608, doi:10.1055/a-0681-6608. This article has 18 citations.](https://doi.org/10.1055/a-0681-6608)

[8. (Matsushima2020Anosmin1) Shoko Matsushima, Akio Shimizu, Manami Kondo, Hirotsugu Asano, Nobuhiro Ueno, Hironao Nakayama, Naoko Sato, Masahiro Komeno, Hisakazu Ogita, and Misuzu Kurokawa-Seo. Anosmin-1 activates vascular endothelial growth factor receptor and its related signaling pathway for olfactory bulb angiogenesis. Scientific Reports, January 2020. URL: http://dx.doi.org/10.1038/s41598-019-57040-3, doi:10.1038/s41598-019-57040-3. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-57040-3)

[9. (de2016ANOS1:) Fernando de Castro, Ruth Seal, and Roberto Maggi. Anos1: a unified nomenclature for kallmann syndrome 1 gene (kal1) and anosmin-1. Briefings in Functional Genomics, 16(4):205–210, November 2016. URL: http://dx.doi.org/10.1093/bfgp/elw037, doi:10.1093/bfgp/elw037. This article has 34 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/bfgp/elw037)

[10. (Esteban2012The) Pedro F. Esteban, Verónica Murcia‐Belmonte, Diego García‐González, and Fernando de Castro. The cysteine‐rich region and the whey acidic protein domain are essential for anosmin‐1 biological functions. Journal of Neurochemistry, 124(5):708–720, December 2012. URL: http://dx.doi.org/10.1111/jnc.12104, doi:10.1111/jnc.12104. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/jnc.12104)

[11. (Kałużna2021Defects) Małgorzata Kałużna, Bartłomiej Budny, Michał Rabijewski, Jarosław Kałużny, Agnieszka Dubiel, Małgorzata Trofimiuk-Müldner, Elżbieta Wrotkowska, Alicja Hubalewska-Dydejczyk, Marek Ruchała, and Katarzyna Ziemnicka. Defects in gnrh neuron migration/development and hypothalamic-pituitary signaling impact clinical variability of kallmann syndrome. Genes, 12(6):868, June 2021. URL: http://dx.doi.org/10.3390/genes12060868, doi:10.3390/genes12060868. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes12060868)

[12. (Chu2023Mutation) Guoming Chu, Pingping Li, Qian Zhao, Rong He, and Yanyan Zhao. Mutation spectrum of kallmann syndrome: identification of five novel mutations across anos1 and fgfr1. Reproductive Biology and Endocrinology, March 2023. URL: http://dx.doi.org/10.1186/s12958-023-01074-w, doi:10.1186/s12958-023-01074-w. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12958-023-01074-w)

[13. (GonzálezMartínez2004Anosmin1) David González-Martínez, Soo-Hyun Kim, Youli Hu, Scott Guimond, Jonathan Schofield, Paul Winyard, Gabriella Barbara Vannelli, Jeremy Turnbull, and Pierre-Marc Bouloux. Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism. The Journal of Neuroscience, 24(46):10384–10392, November 2004. URL: http://dx.doi.org/10.1523/JNEUROSCI.3400-04.2004, doi:10.1523/jneurosci.3400-04.2004. This article has 181 citations.](https://doi.org/10.1523/JNEUROSCI.3400-04.2004)